1. Home
  2. OSIS vs AKRO Comparison

OSIS vs AKRO Comparison

Compare OSIS & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OSIS
  • AKRO
  • Stock Information
  • Founded
  • OSIS 1987
  • AKRO 2017
  • Country
  • OSIS United States
  • AKRO United States
  • Employees
  • OSIS N/A
  • AKRO N/A
  • Industry
  • OSIS Industrial Machinery/Components
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • OSIS Technology
  • AKRO Health Care
  • Exchange
  • OSIS Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • OSIS 4.2B
  • AKRO 3.7B
  • IPO Year
  • OSIS 1997
  • AKRO 2019
  • Fundamental
  • Price
  • OSIS $287.84
  • AKRO $54.12
  • Analyst Decision
  • OSIS Strong Buy
  • AKRO Buy
  • Analyst Count
  • OSIS 6
  • AKRO 10
  • Target Price
  • OSIS $260.83
  • AKRO $73.56
  • AVG Volume (30 Days)
  • OSIS 169.4K
  • AKRO 1.8M
  • Earning Date
  • OSIS 10-30-2025
  • AKRO 11-07-2025
  • Dividend Yield
  • OSIS N/A
  • AKRO N/A
  • EPS Growth
  • OSIS 14.72
  • AKRO N/A
  • EPS
  • OSIS 8.81
  • AKRO N/A
  • Revenue
  • OSIS $1,753,782,000.00
  • AKRO N/A
  • Revenue This Year
  • OSIS $8.98
  • AKRO N/A
  • Revenue Next Year
  • OSIS $5.46
  • AKRO N/A
  • P/E Ratio
  • OSIS $32.32
  • AKRO N/A
  • Revenue Growth
  • OSIS 9.37
  • AKRO N/A
  • 52 Week Low
  • OSIS $149.68
  • AKRO $21.34
  • 52 Week High
  • OSIS $288.64
  • AKRO $58.40
  • Technical
  • Relative Strength Index (RSI)
  • OSIS 69.85
  • AKRO 68.19
  • Support Level
  • OSIS $271.47
  • AKRO $53.90
  • Resistance Level
  • OSIS $288.64
  • AKRO $54.31
  • Average True Range (ATR)
  • OSIS 9.92
  • AKRO 0.23
  • MACD
  • OSIS 2.94
  • AKRO -0.25
  • Stochastic Oscillator
  • OSIS 94.43
  • AKRO 80.66

About OSIS OSI Systems Inc. (DE)

OSI Systems Inc is a designer and manufacturer of electronic systems and components for businesses in the homeland security, healthcare, defense, and aerospace markets. The firm is organized in three business segments: Security, which derives maximum revenue, provides security and inspection systems; Healthcare, which provides patient monitoring, diagnostic, cardiology, ventilation systems, and defibrillators; and Optoelectronics and Manufacturing, which provides specialized electronic components and manufacturing services for the Security and Healthcare segments and external original equipment manufacturers. The majority of the firm's revenue is generated in the United States, and the rest from Mexico, Europe, the Middle East and Africa, and the Asia Pacific regions.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: